Is Enasidenib a cytoplasmic agent?

Enasidenib (Enasidenib) is not cytotoxic. Ensidipine is a targeted drug used to treat a subtype of leukemia called acute myeloid leukemia (AML), specifically those with mutations in the IDH2 gene. It is an IDH2 inhibitor that interferes with the growth and division of AML cells by interfering with the abnormal protein produced by mutations in the IDH2 gene.

Ensidipine's main target is the abnormal metabolic pathways of malignant cells, not the cells. Its role is to inhibit the proliferation and survival of leukemia cells by regulating cell metabolism and reducing the accumulation of abnormal metabolites. Ensidipine is not effective in all patients and its effectiveness varies among individuals. Before using ensidipine, you should have a detailed discussion with your doctor to develop a suitable treatment plan, be patient during the treatment process, and follow the doctor's instructions to obtain the best treatment effect.

Encidipine research medicine is not currently on the market in China, so it cannot be included in medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic ensidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*30 tablets produced by a Laos pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to the exchange rate). Its pharmaceutical ingredients are basically the same as those of the original drugs sold abroad. For more information on overseas drug prices and specific information, please consult Yaode Medical Consultant.